Cargando…
Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas
Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. We report the use of everolimus for the compassionate treatment of four eld...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794648/ https://www.ncbi.nlm.nih.gov/pubmed/24175104 http://dx.doi.org/10.1155/2013/604301 |
_version_ | 1782287238448545792 |
---|---|
author | Eibenschutz, Laura Colombo, Delia Catricalà, Caterina |
author_facet | Eibenschutz, Laura Colombo, Delia Catricalà, Caterina |
author_sort | Eibenschutz, Laura |
collection | PubMed |
description | Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. We report the use of everolimus for the compassionate treatment of four elderly, nontransplant patients presenting with multiple basal cell carcinomas (BCC). All patients had a long history of BCC, had refused surgery as a current treatment option, and did not respond to alternative treatments (including topical 5-fluorouracil and imiquimod). Patients were treated with oral everolimus (1.5–3.0 mg daily) for 12 months or longer: a complete and sustained response was seen in one case, and partial responses were seen in two other cases. Everolimus was well tolerated in these elderly patients. These promising preliminary data suggest that further dose-finding, controlled clinical studies are warranted to evaluate the antineoplastic effects of everolimus in patients affected by BCC who cannot or will not undergo surgery. |
format | Online Article Text |
id | pubmed-3794648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37946482013-10-30 Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas Eibenschutz, Laura Colombo, Delia Catricalà, Caterina Case Rep Dermatol Med Case Report Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. We report the use of everolimus for the compassionate treatment of four elderly, nontransplant patients presenting with multiple basal cell carcinomas (BCC). All patients had a long history of BCC, had refused surgery as a current treatment option, and did not respond to alternative treatments (including topical 5-fluorouracil and imiquimod). Patients were treated with oral everolimus (1.5–3.0 mg daily) for 12 months or longer: a complete and sustained response was seen in one case, and partial responses were seen in two other cases. Everolimus was well tolerated in these elderly patients. These promising preliminary data suggest that further dose-finding, controlled clinical studies are warranted to evaluate the antineoplastic effects of everolimus in patients affected by BCC who cannot or will not undergo surgery. Hindawi Publishing Corporation 2013 2013-09-23 /pmc/articles/PMC3794648/ /pubmed/24175104 http://dx.doi.org/10.1155/2013/604301 Text en Copyright © 2013 Laura Eibenschutz et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Eibenschutz, Laura Colombo, Delia Catricalà, Caterina Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
title | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
title_full | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
title_fullStr | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
title_full_unstemmed | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
title_short | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
title_sort | everolimus for compassionate use in multiple basal cell carcinomas |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794648/ https://www.ncbi.nlm.nih.gov/pubmed/24175104 http://dx.doi.org/10.1155/2013/604301 |
work_keys_str_mv | AT eibenschutzlaura everolimusforcompassionateuseinmultiplebasalcellcarcinomas AT colombodelia everolimusforcompassionateuseinmultiplebasalcellcarcinomas AT catricalacaterina everolimusforcompassionateuseinmultiplebasalcellcarcinomas |